RxDoctor Payments Data

Lindsay Hannan, MD

Hematology & Oncology · Atlanta, GANPI 1821434234

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, AstraZeneca. That places this record below the midpoint for hematology & oncology clinicians in GA, where the typical reported total is $4,479.

$91in general payments, 2019–2025

Across 1 payment — averaging $91.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$91
$120,384in research payments, 2019–2025

Across 6 payments — averaging $20,064 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$61K
  • Coherus Oncology, Inc.$40K
  • AstraZeneca$20K

What the payments were for

  • Food & beverage$91100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$91

How this compares

$91 in reported general payments places this provider in the 5th percentile of 370 hematology & oncology providers in Georgia.

See all hematology & oncology providers in Georgia

Medicare billing

Part B allowed, 2024
$23,516
Medicare patients
98
Services billed
208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase15$36,673
ZarxioFilgrastim-Sndz13$22,968
Prochlorperazine Maleate106$1,127
Dexamethasone83$620
Oxycodone Hcl60$519
Ondansetron Hcl63$357
Mirtazapine25$319
Pantoprazole Sodium13$158
Lidocaine-PrilocaineLidocaine/Prilocaine11$124
Furosemide12$27

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →